Angela Harris
Medical · Dearborn, MINPI 1144656935
Payments from drug & device makers
Across 367 payments — averaging $16.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$751
- Amgen$634
- Lilly USA, LLC$421
- Pfizer$420
- AbbVie$362
- Sanofi-aventis U.S. LLC$313
- plus $3K from 44 others
What the payments were for
- Food & beverage$5,982100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$5,982 in reported general payments places this provider in the 85th percentile of 755 medical providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 40 | $47,298 |
| WegovySemaglutide | 23 | $30,167 |
| OzempicSemaglutide | 25 | $27,373 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $23,017 |
| EliquisApixaban | 17 | $20,750 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 11 | $17,282 |
| GemtesaVibegron | 16 | $14,408 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 14 | $10,444 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $9,559 |
| LinzessLinaclotide | 13 | $6,892 |
| Repatha SyringeEvolocumab | 12 | $6,602 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 23 | $4,135 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 175 | $3,728 |
| Levothyroxine Sodium | 75 | $1,740 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 45 | $1,540 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskWegovy, Ozempic | $751 | $57,54048 claims |
| Lilly USA, LLCMounjaro | $421 | $47,29840 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $225 | $32,57641 claims |
| PfizerEliquis | $420 | $20,75017 claims |
| Orexo US, Inc.Zubsolv | $72 | $17,28211 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $56 | $14,40816 claims |
| Indivior Inc.Suboxone | $46 | $10,44414 claims |
| AbbVieLinzess | $362 | $6,89213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 755 medical providers in Michigan.
Other medical in Dearborn
- Kristie GreearDearborn$10K
- Caleb YoungbloodBerkley$215K
- Steven StoneKalamazoo$200K
- Meredith KentGrand Rapids$192K
- Amber ShullNorton Shores$154K
- Jason EvansWaterford$104K
- James ToreySaint Clair Shores$66K
- David WilkinsMuskegon$41K
- Mark RosenBerkley$32K
- Robert DemeesterRoyal Oak$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.